pancreatic endocrine tumor

pancreatic endocrine tumor

A neoplasm of the endocrine pancreas–eg, Apudoma, islet cell tumor, nesidioblastoma, common in the body and tail, the sites of ↑ concentration of islets of Langerhans; PETs are seen in 0.5-1.0% of unselected autopsies, hormonally active tumors comprise < 1:105; PET names reflect the predominant hormone–eg, gastrinoma, glucagonoma, VIPoma, PPoma etc, although most PETs produce ≥ 1 hormone Prognosis Most PETs are indolent with a 10-yr survival post-resection; aggressive PETs may need chemotherapy, streptozocin. See Endocrine pancreas, WDHA syndrome, Zollinger-Ellison syndrome.
References in periodicals archive ?
Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.
It also reviews key players involved in the therapeutic development for Pancreatic Endocrine Tumor and special features on late-stage and discontinued projects.
Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor.
Differential diagnosis includes nonfunctional pancreatic endocrine tumor, acinar cell carcinoma, solid pseudopapillary tumor and adenocarcinoma (15).
INTRODUCTION: Insulinoma is the most common pancreatic endocrine tumor that is typically sporadic solitary and less than 2 cm in diameter.
Intrapancreatic accessory spleen: mimic of pancreatic endocrine tumor diagnosed by endoscopic ultrasound-guided fine-needle aspiration biopsy.
It has been suggested that this neoplasm be named pancreatic endocrine tumor with entrapped ductules (83) to describe the nonneoplastic nature of the ductules.
Sensitivities for specific diagnostic entities were as follows: 79% for ductal adenocarcinoma, 100% for acinar cell carcinoma, 75% for pancreatic endocrine tumor, 70% for intraductal papillary mucinous neoplasms (IPMN), and 42% for mucinous cystic neoplasms (MCN).
Pancreatic endocrine neoplasm: epidemiology and prognosis of pancreatic endocrine tumors.
In pancreatic endocrine tumors, curative resection improved the survival of many patients with non-functioning neuroendocrine neoplasm of the pancreas.
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.